ZVRA vs SANA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZVRA · Zevra Therapeutics$11.59 ▲ 10.07%
SANA · Sana Biotechnology$2.37 ▲ 1.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZVRA +27.4%
- SANA -42.5%
Head to head
| Metric | ZVRA | SANA |
|---|---|---|
| Price | $11.59 | $2.37 |
| Change today | ▲ 10.07% | ▲ 1.28% |
| Market cap | $689.66M | $710.13M |
| Return, 3 months | +1.0% | -34.3% |
| Return, year to date | +29.4% | -41.8% |
| Return, 1 year | +31.6% | -42.1% |
| P/E (TTM) | 9.5 | -4.6 |
| P/B | 2.9 | 3.9 |
| P/E percentile vs own 5y | 84th | 57th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +53.3% | – |
| Net profit growth (YoY) | -88.3% | +32.2% |
| Gross margin | 95.5% | – |
| Operating margin | 28.7% | – |
| Net margin | 42.8% | – |
| Return on equity | 34.8% | -152.9% |
| Analyst target vs. price | +117.9% | +237.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 60 | 42 |
| 30-day volatility | 67.4% | 67.2% |
| Max drawdown, 1 year | -35.5% | -59.4% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SANA is the largest of the group by market value.
- ZVRA has returned the most over the past year.
- SANA carries the lowest trailing P/E.
- SANA has been the calmest stock over the last 30 days.